Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.it

Coloplast Finance B.V. - Annual Report, 2023/24

Hereby please find the Annual Report 2023/24 for the group of Coloplast A/S. Attachment 07_2024_Annual_Report_2023-24

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent…

~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~~ Presented positive interim data from Phase I/II trial of AMT-130 demonstrating slowing of Huntington's disease progression and reductions in key biomarker of neurodegeneration ~~ Initiated patient dosing in new Phase I/II studies of AMT-162 in SOD1-ALS and AMT-191 in Fabry disease; First...

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate…

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease (PD) on track to report interim safety and immunogenicity dataPrescreening rate for Phase 2b Retain trial of JNJ-2056 (ACI-35.030) in Alzheimer's disease (AD) triggered CHF 24.6 million milestone under agreementJNJ-2056 received Fast Track designation from the U.S. FDACash of CHF 157.9 million at the end of September, plus the CHF 24...

Sanitas, one of Switzerland's largest health insurers, embeds Lifelight's vital…

Now with the inclusion of Lifelight, Sanitas is taking a proactive approach to further mitigate health risks. A chronic illness guide within the app focuses on prevention, detection and management of cardiovascular disease (CVD) through early monitoring and pre-emptive intervention. Now with the inclusion of Lifelight, Sanitas is taking a proactive approach to further mitigate health risks. A chronic illness guide within the app focuses on prevention, detection and management of...

Xeltis expands leadership team with appointment of Luc Verhees as Vice President…

Eliane Schutte, Chief Executive Officer, Xeltis commented: "As we progress our clinical programs and push towards commercializing aXess, Luc brings great knowledge and familiarity of the clinical trials landscape across multiple continents. Luc's skills and track record will be invaluable as we prepare to initiate our US pivotal trial for aXess." Eliane Schutte, Chief Executive Officer, Xeltis commented : "As we progress our clinical programs and push towards commercializing…

INTRODUCING JUICE PLUS+ LUMINATE: ONE OF THE FIRST, RAPID ACTING, PLANT-BASED…

In today's fast-paced world, the pressures of daily life can take a toll on our cognitive function, leading to fatigue and challenges concentrating. New consumer research by Juice Plus+ that polled over 12,000 people[6], uncovered a growing trend in procrastination, with nearly 78% experiencing difficulty keeping focused on tasks. The data also found that people are spending over 5 hours of the day unfocused. Whether managing a demanding workload, studying for long hours, or balancing...

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin 1. Reported revenue in DKK grew 10% to DKK 27,030 million.Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 11%, Advanced Wound Care 10% (Advanced Wound Dressings 8%) and Interventional Urology 5%. Kerecis contributed 4%-points to reported growth, with an underlying growth of around 35%, in line with expectations...

Coloplast A/S - Full-Year Financial Results 2023/24

2023/24 Announcement of full-year financial results1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin 1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months).Organic growth rates by business area: Ostomy Care 6%, Continence Care 10%, Voice and Respiratory Care 12%, Advanced Wound Care 10% (Advanced Wound Dressings...

Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive…

Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect.“We have entered the final year of our 2025 strategy. In this strategic period, Coloplast has made significant investments to expand the reach of the company and build four growth platforms, Chronic Care, Voice & Respiratory Care, Advanced Wound Care and Interventional Urology, which must drive value creation in the years...

NorthWest EHealth (NWEH) announces a pilot to test a new model for finding and…

NWEH's FARSITE is a secure platform that enables rapid feasibility across a representative population, while preserving participant anonymity. It accurately finds potential trial participants with pin-point accuracy through easy-to-use inclusion and exclusion criteria when inputting information. This unlocks potential participant pools for find-and-refer services who are then contacted directly by their GP practices, increasing opportunities for people to participate in clinical trials…

Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the…

Key Takeaways from the Exosomes-based Therapies Pipeline Report Key Takeaways from the Exosomes-based Therapies Pipeline Report Request a sample and discover the recent advances in exosomes-based therapies @ Exosomes Pipeline Outlook The exosomes-based therapies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage exosomes-based therapies, inactive and dormant assets, a comprehensive assessment of driving and...

Nyxoah Appoints John Landry as Chief Financial Officer

Nyxoah Appoints John Landry as Chief Financial OfficerCurrent CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024,10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial...

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash...

David Meek is proposed as new Chair of the Board of Directors of Sobi

Annette Clancy has informed the Nomination Committee that she will not be available for re-election as Chair or ordinary member of the Board of Directors at the Annual General Meeting 2025. However, she will remain an ordinary member of the Board until that time. Annette Clancyhas informed the Nomination Committee that she will not be available for re-election as Chair or ordinary member of the Board of Directors at the Annual General Meeting 2025. However, she will remain an ordinary member...

Global Oncology Pharmaceuticals Market: Revolutionizing Cancer Care Worldwide

This report offers a detailed look at the global market for oncology pharmaceuticals, which are medications used to treat cancer. It covers different types of cancer drugs, including targeted therapies, immunotherapies, chemotherapies, and hormone therapies. The report also examines the market's current and past revenue, breaking it down by specific cancers like lung cancer, breast cancer, and others. This report offers a detailed look at the global market for oncology pharmaceuticals, which...

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in…

GLORIA, the world's 1 stphase II phage therapy study in the treatment of Prosthetic Joint Infections (PJI) related to Staphylococcusaureus The clinical protocol also being submitted to the European health authorities and the MHRA in the UKPatients recruitment scheduled to start in Q1 2025 for clinical data readout expected in Q3 2026 Lyon (France), November 04, 2024 – 6:00 pm CET - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), abiopharmaceutical company developing...

Reporting of transactions made by persons discharging managerial…

Company announcement no. 10 - 244 November 2024 Reporting of transactions made by persons discharging managerial responsibilities, and persons closely associated with them, in NTG's shares In accordance with section 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation), NTG Nordic Transport Group A/S (“NTG”), CVR no. 12546106, hereby announces receipt of the following notification from persons...

Artificial Intelligence in Pathology Market to Hit USD 169.8 Million by 2029…

Browse in-depth TOC on "Artificial Intelligence in Pathology Market" Browse in-depth TOC on "Artificial Intelligence in Pathology Market" 250 - Tables 50 - Figures 300 - Pages By neural networks, the AI in pathology market is segmented into generative adversarial networks (GAN), convolutional neural networks (CNN), recurrent neural networks (RNN), and others. The convolutional neural network segment accounted for the largest share of AI in pathology market in 2023. The…

Home Automation System Market worth $73.49 billion by 2029 - Exclusive Report by…

Browse in-depth TOC on "Home Automation System Market" 150 – Tables90 – Figures210 – Pages Browse in-depth TOC on "Home Automation System Market" 150 – Tables 90 – Figures 210 – Pages Home Automation System Market Report Scope: By Installation type: new installations segment to account for the larger market share in the forecasted year. The new installation segment accounted for the larger share of the home automation system market in 2029. The growth of the segment is...

Coloplast Finance B.V. - Annual Report, 2023/24

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent…

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate…

Particle Counters Market to Hit USD 986.3 Million by 2029 with 9.5% CAGR |…

Endo Reports Third-Quarter 2024 Financial Results and Reaffirms 2024 Financial…

Rhino Rescue Empowers First Aid Training Program in Mexico, Further Elevating…

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating…

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

Sanitas, one of Switzerland's largest health insurers, embeds Lifelight's vital…

Xeltis expands leadership team with appointment of Luc Verhees as Vice President…

INTRODUCING JUICE PLUS+ LUMINATE: ONE OF THE FIRST, RAPID ACTING, PLANT-BASED…

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Coloplast A/S - Full-Year Financial Results 2023/24

Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive…

NorthWest EHealth (NWEH) announces a pilot to test a new model for finding and…

Exosome Therapies on the Rise as 70+ Major Companies Driving Development in the…

Nyxoah Appoints John Landry as Chief Financial Officer

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

David Meek is proposed as new Chair of the Board of Directors of Sobi

Global Oncology Pharmaceuticals Market: Revolutionizing Cancer Care Worldwide

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in…

Reporting of transactions made by persons discharging managerial…

Artificial Intelligence in Pathology Market to Hit USD 169.8 Million by 2029…

Home Automation System Market worth $73.49 billion by 2029 - Exclusive Report by…